News

EU fuels rare diseases research
Enlarge image

FundingFranceUKGermanyEU

EU fuels rare diseases research

28.01.2013 - The European Commission has kicked off four projects, worth €38m, to improve diagnosis and therapy of rare diseases.

According to the University of Manchester, the European Commission has announced the €38m funding in Barcelona. The money will be channelled into four projects over the next six years: the EURenOmics project aims at identifying genetic and epigenetic roots of rare kidney disorders. It is funded with about €12m and will be coordinated by Heidelberg University Medical Centre, Germany. The Neuromics consortium, which was kicked off last November with funding of almost €12m, will look after biomarkers for rare neurodegenerative and neuromuscular disorders using next generation whole-exome sequencing.  It is led by the University of Tübingen, Germany. Coordination is high on the agenda of the RD-Connect project led by Newcastle University, UK. Funded with around €12m it aims at developing a global infrastructure to share the -omics data of rare disease projects from 70 institutions.  Finally, a communication project called SUPPORT-IRDiRC led by INSERM, France, will receive about €2m.

Orphan diseases have been more and more in the focus of biopharmaceutical companies because they promise fast-track approvals, long market exclusivity and high reimbursement. All projects are part of the International Rare Diseases Research Consortium (IRDiRC). That joint initiative was launched in 2011 to improve diagnosis and treatment of orphan diseases, by identifying the underlying genetic defect through genomics tools. The initiative aims at pooling data and expertise around the world to standardise research. 

Around 80% of the known rare diseases have a genetic component.  The researchers hope to solve the challenge of identifying disease biomarkers by using Next generation sequencing, which allows identification of mutations in a complete set of human genes for several thousands of euros within ten days and subsequent data analysis.  Professor Paul Lasko of McGill University in Montréal, Canada, Chair-Elect of the IRDiRC Executive Committee, explained: "IRDiRC's goal is to reach 200 new rare disease therapies, and diagnoses for all rare diseases, by the year 2020. To this end, it is today launching three major projects which will combine international genetic data with clinical information and data on biomaterials to help interpret the vast amounts of data the genome yields. This will aid scientists in the search for the genetic cause of diseases and help identify new ways to create targeted therapies". Approximately 30 million people across Europe are affected by a rare disease. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/eu-fuels-rare-diseases-research.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%

FLOP

  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%

TOP

  • 4SC4.65 EUR257.7%
  • SYNGENTA430.80 CHF31.8%
  • EVOLVA1.84 CHF21.1%

FLOP

  • CYTOS0.66 CHF-35.3%
  • MEDIGENE8.43 EUR-30.7%
  • CO.DON2.85 EUR-17.4%

TOP

  • WILEX3.95 EUR393.7%
  • 4SC4.65 EUR322.7%
  • FORMYCON28.39 EUR311.4%

FLOP

  • MOLOGEN5.05 EUR-53.4%
  • BIOFRONTERA2.29 EUR-24.9%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.05.2015